Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis

Table 1 Baseline characteristics of patients in the two groups

Group	Gender (male/female)	Age (yr)	Average age (yr)	Primary lesion site (n)		Metastasis site (n)
				Left-sided colorectal	Right-sided colon	Liver	Bone	Lung	Abdominal cavity
Observation group (n = 47)	23/24	60-83	72.25 ± 6.41	31	16	19	12	11	5
Control group (n = 47)	22/25	60-82	72.19 ± 6.37	30	17	18	13	10	6

Table 2 Recent therapeutic effects in the two groups

Group	CR	PR	SD	PD	DCR
Observation group (n = 47)	0	11 (23.40)	17 (36.17)	19 (40.43)	28 (59.57)
Control group (n = 47)	0	10 (21.28)	16 (34.04)	21 (44.68)	26 (55.32)
χ2					0.174
P value					0.677

CR: Complete remission; PR: Complete remission; SD: Stable disease; PD: Progression of disease; DCR: Disease control rate.

Table 3 Incidence of adverse reactions during treatment in the two groups

Group	HFSR	Anemia	Hepatic insufficiency	Weakness	Nausea and vomiting	Neutropenia
Observation group (n = 47)	10 (21.28)	2 (4.26)	2 (4.26)	7 (14.89)	14 (29.79)	14 (29.79)
Control group (n = 47)	9 (19.15)	1 (2.13)	2 (4.26)	5 (10.64)	12 (25.53)	12 (25.53)
χ2	0.066	0	0.261	0.382	0.213	0.213
P value	0.797	1	0.609	0.536	0.645	0.645

HFSR: Hand-foot skin reaction.

Table 4 Levels of serum carcinoembryonic antigen, carbohydrate antigen 199, carbohydrate antigen 125 in the two groups

Group	CEA (μg/mL)		CA199 (U/mL)		CA125 (U/mL)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Observation group (n = 47)	8.22 ± 0.76	1.53 ± 0.12a	50.63 ± 4.75	20.67 ± 2.01a	72.90 ± 7.04	43.09 ± 5.63a
Control group (n = 47)	8.35 ± 0.71	3.91 ± 0.19a	51.22 ± 4.92	39.54 ± 2.76a	72.83 ± 7.12	45.13 ± 6.97a
χ2	0.857	72.607	0.591	37.889	0.038	2.247
P value	0.3197	< 0.001	0.278	< 0.001	0.97	0.0217

^aP < 0.05. Serum tumor marker levels of carcinoembryonic antigen, carbohydrate antigen (CA) 199 and CA125 in the control and observation groups. CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen.